Igf1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Full Name | IGF-1 (Insulin-like Growth Factor 1, Somatomedin C) |
|---|
| Chromosome | chr12 |
|---|
| Location | 12q23.2 |
|---|
| NCBI Gene ID | 3479 |
|---|
| OMIM | 147440 |
|---|
| Ensembl | ENSG00000117471 |
|---|
| UniProt | P05019 |
|---|
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Laron Syndrome |
|---|
| Protein Class | Growth Factor, Insulin-like Peptide |
|---|
| Expression | Brain, Liver, Peripheral tissues |
|---|
IGF1 (Insulin-like Growth Factor 1) is a 70-amino acid peptide growth factor that plays essential roles in brain development, neuronal survival, synaptic plasticity, and overall nervous system function. Often called "Somatomedin C," IGF1 is produced both centrally in the brain (by neurons and glia) and peripherally in the liver, with the latter able to cross the blood-brain barrier. IGF1 exerts its effects primarily through the IGF1 receptor (IGF1R), activating the PI3K/Akt and MAPK/ERK signaling cascades that promote cell survival, proliferation, and differentiation. This growth factor has garnered significant attention as a therapeutic target for neurodegenerative diseases due to its potent neuroprotective and neurotrophic properties.
The IGF1 gene is located on chromosome 12q23.2 and spans approximately 80 kb. The gene consists of 6 exons and produces multiple transcript variants through alternative splicing:
- Class 1 transcripts: Include exon 1, encode the classic IGF-1A and IGF-1B isoforms
- Class 2 transcripts: Include exon 2, produce variants with different N-terminal signal peptides
- Ea isoform: The predominant brain isoform
- Eb isoform: Less abundant, alternative splicing
The IGF1 promoter contains response elements for various transcription factors including HNF-3, C/EBP, and AP-1, allowing regulation by nutritional status, hormones, and growth factors.
The mature IGF1 protein is a 70-amino acid peptide (7.6 kDa) with structural homology to insulin:
- B-domain (residues 1-29): Receptor binding
- C-domain (residues 30-35): Connecting peptide
- A-domain (residues 36-70): Receptor binding
- D-domain: Present in some isoforms
IGF1 binds to multiple receptors with different affinities:
- IGF1R: High affinity, primary signaling receptor
- IR (Insulin Receptor): Lower affinity
- IGF2R: IGF1 binding triggers internalization (no signaling)
The IGF1R is a receptor tyrosine kinase (RTK) that dimerizes upon ligand binding.
During brain development, IGF1 plays crucial roles:
- Neuronal proliferation and differentiation
- Axonal growth and guidance
- Synapse formation
- Myelination by oligodendrocytes
- Astrocyte function
IGF1 provides potent neuroprotection through multiple mechanisms:
- Anti-apoptotic: Activates PI3K/Akt pathway, inhibiting caspase activation
- Anti-excitotoxic: Modulates glutamate receptor function
- Antioxidant: Upregulates antioxidant enzymes
- Anti-inflammatory: Reduces microglial activation
IGF1 modulates synaptic function:
- Enhances long-term potentiation (LTP)
- Regulates AMPA receptor trafficking
- Promotes dendritic spine formation
- Supports learning and memory
IGF1 promotes neural stem cell function:
- Stimulates proliferation in subventricular zone
- Enhances differentiation
- Improves survival of new neurons
IGF1 signaling is impaired in AD:
- Reduced IGF1 levels in AD brains
- Impaired PI3K/Akt signaling
- Contributes to synaptic loss
- Therapeutic potential of IGF1 delivery
- Decreased IGF1 in substantia nigra
- Protects dopaminergic neurons
- IGF1 therapy shows promise in models
- Clinical trials ongoing
- Dysregulated IGF1 in ALS patients
- IGF1 gene therapy ( AAV) in trials
- Protects motor neurons
- Modulates neuroinflammation
- IGF1 signaling defects
- Mutant huntingtin disrupts IGF1 signaling
- Therapeutic targeting in development
- IGF1 deficiency due to GH receptor mutations
- Neurodevelopmental consequences
- IGF1 treatment benefits
IGF1 exhibits widespread but region-specific expression:
- High Expression: Hippocampus (CA1-CA3, dentate gyrus), cortex (layers II-VI), cerebellum (Purkinje cells), olfactory bulb
- Moderate Expression: Basal ganglia, thalamus, hypothalamus
- Cell Types: Neurons, astrocytes, oligodendrocytes, microglia
Peripheral expression is highest in the liver, with additional production in kidney, muscle, and heart.
IGF1 binds to IGF1R, causing:
- Receptor dimerization
- Autophosphorylation
- Recruitment of adapter proteins (IRS-1/2, Shc)
- Activation of downstream pathways
Primary survival pathway:
- Akt phosphorylation inhibits pro-apoptotic proteins (Bad, FoxO)
- mTORC1 activation promotes protein synthesis
- GSK-3β inhibition protects against tau pathology
Growth and differentiation:
- Ras/Raf/MEK/ERK cascade
- Gene transcription
- Cell growth and differentiation
- Synaptic plasticity
IGF1 interacts with other pathways:
- mTOR: Integration with nutrient signaling
- Notch: Neurodevelopmental cross-talk
- Wnt: Developmental interactions
- Mecasermin (Increlex): FDA-approved for GH insensitivity
- Intranasal delivery: Bypasses BBB
- Subcutaneous administration: Systemic delivery
- Clinical trials: AD, PD, ALS
- AAV-IGF1 delivery to brain
- Promising in ALS models
- Ongoing clinical trials
- IGF1 mimetics
- IGF1R-selective compounds
- Brain-penetrant options
- IGF1 + neurotrophic factors
- IGF1 + stem cell therapy
- IGF1 + anti-amyloid approaches
- Complete KO: Perinatal lethal, growth deficiency
- Neuron-specific KO: Learning deficits
- Conditional KO: Age-related neurodegeneration
- Overexpression: Enhanced neurogenesis
- Disease models: AD, PD, HD
- Reporter lines
- GH receptor knockout
- IGF1 deficiency
- Therapeutic testing
- Brain-penetrant IGF1 mimetics
- Intranasal delivery optimization
- Gene therapy clinical translation
- Biomarker development
- Combination therapy approaches
The study of Igf1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.